$VIVS

Investor interest is growing in four small-cap stocks: VivoSim Labs (VIVS), IGC Pharma (IGC), Algorhythm Holdings (RIME), and Xiao-I (AIXI). VIVS reported a $5M milestone payment from Eli Lilly and targets 500%+ revenue growth. IGC beat Q2 estimates and expects Alzheimer's trial results in Q4. RIME is exploring strategic alternatives for its SemiCab AI logistics business. AIXI focuses on enterprise AI solutions. All four stocks trade near $0.30.

VivoSim Labs (VIVS) received a notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement. The company has 180 days to comply, considering a reverse stock split, and continues trading on the Nasdaq Capital Market.

Esousa Group Holdings LLC and Michael Wachs together own 9.9% of VivoSim Labs (VIVS) common stock, or 319,429 shares, as of June 30, 2026. They hold warrants for 576,542 additional shares but cannot exercise them to exceed the 9.9% ownership limit. They have sole voting and dispositive power over the 319,429 shares.

VivoSim Labs (NASDAQ: VIVS) says FDA draft guidance on New Approach Methodologies is advancing human-relevant drug toxicity testing. The company reported 91% predictive accuracy for liver toxicity and 96% for AI GI diarrhea training. VivoSim also announced first China commercial sales and a $5 million Eli Lilly (NYSE: LLY) Phase 2 milestone, with up to $45 million more, plus 500%+ FY2027 revenue growth guidance.

VivoSim Labs (NASDAQ: VIVS) filed a preliminary proxy seeking stockholder approval at a fully virtual Sept. 30, 2026 annual meeting. Proposals include electing two directors, ratifying Rosenberg Rich Baker Berman P.A. as auditor, a say-on-pay vote, authorizing a board-discretionary reverse split, amending its 2022 equity plan, and approving warrant-related share issuance up to 4,705,883 shares.

VIVOSIM LABS (VIVS) is set to report Q1 2026 earnings on Aug. 10 before market open, according to Finnhub. Analysts expect revenue of $47.94 million and EPS of -$0.19. The article also cites recent institutional activity, including adds by Geode Capital and Goldman Sachs and reductions by Citadel and Two Sigma.

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

VivoSim Labs said Nasdaq notified it on July 20, 2026 that it failed Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity, and it did not qualify under alternative standards. The company has 45 days to submit a compliance plan, with a possible extension to Jan. 16, 2027. Trading remains on Nasdaq under VIVS.